Dr. Kevin Alexander and Dr. C Michael Gibson discuss: Acoramidis Effect on All-Cause Mortality in Patients with p.V142I (V122I) Variant ATTR-CM: Findings From the ATTRibute-CM Study
Disclosures: Supported by an independent educational grant from BridgeBio Pharma Inc.